BioNano Genomics Inc vs Expedia Group Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Expedia Group Inc trades at $320.5 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 2820.6× BioNano Genomics Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | EXPE | |
|---|---|---|
Market Cap | $13.66M | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $321.07 |
52-Week Low | $1.06 | $188.51 |
Enterprise Value | $16.26M | $37.09B |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.
Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →